Jezebel has been the Internet's most treasured source for everything celebrities, sex, and politics...with teeth.

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025. The post ResMed shares are up 42% in ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

While GLP-1 medications like Ozempic and Wegovy have garnered significant attention, bariatric surgery continues to ...

A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Popular weight loss medications seem to be slimming down more than just waistlines. Some companies having to alter their ...